Document is current
Any future updates will be listed below
-
Authors
Maher, Keri R.
Shafer, Danielle
Schaar, Dale
Bandyopadhyay, Dipankar
Deng, Xiaoyan
Wright, John
Piekarz, Richard
Rudek, Michelle A.
Harvey, R. Donald
Grant, Steven
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct03772925 at ClinicalTrials.govDocuments that mention this clinical trial
A phase I study of MLN4924 and belinostat in relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome
https://doi.org/10.1007/s00280-024-04742-9
Pevonedistat plus belinostat in relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome: A phase I multicenter study.
https://doi.org/10.1200/jco.2023.41.16_suppl.e19015
-
Funding
Funding for this research was provided by:
Winn Career Development Award
NIH-NCI Cancer Center Support Grant (P30 CA016059)
NIH-NCI Cancer Center Support Grant (P30 CA016059)
NIH-NCI Cancer Center Support Grant (P30 CA016059)
NIH-NCI Cancer Center Support Grant (P30 CA016059)
NIH: ETCTN (UM1CA186644)
NIH: ETCTN (UM1CA186644)
NIH: ETCTN (UM1CA186644)
NIH: ETCTN (UM1CA186644)
NIH: ETCTN (UM1CA186644)
NIH: ETCTN (UM1CA186644)
NIH (P30CA006973)
NIH (P30CA006973)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Shared Instrument Grant (S10OD020091)
National Center for Advancing Translational Sciences (UL1TR003098)
Leukemia and Lymphoma Society (R6508-18)
- License Information
-
More Information
Article History
Received: 9 August 2024
Accepted: 9 December 2024
First Online: 17 January 2025
Declarations
:
: The authors declare no competing interests.
: NCI Central IRB served as the IRB or Record for this study. All patients provided signed informed consent prior to participation in this study.
